Pricing Log in Create free account

Gyre Therapeutics, Inc. (GYRE) vs REGENXBIO Inc. (RGNX)

Gyre Therapeutics, Inc. and REGENXBIO Inc. are both Biotechnology companies. Gyre Therapeutics, Inc. and REGENXBIO Inc. are of similar size ($533.6M and $493.1M). Gyre Therapeutics, Inc. grew revenue faster over the last twelve months: 13.5% against −4.59%. Gyre Therapeutics, Inc. has the higher net margin (−21.5% vs −113.9%) and the lower return on invested capital (−8.51% vs 0.00%). Across the 17 metrics below, Gyre Therapeutics, Inc. leads on 12 and REGENXBIO Inc. on 5.

Valuation

Metric GYRE RGNX Biotechnology median
P/E n/m n/m 10.85
P/S 4.05 3.39 9.49
P/B 3.41 3.52 2.18
Price to free cash flow n/m n/m 25.85
EV/EBITDA n/m n/m 0.70
EV/Sales 3.48 1.79 8.99
Earnings yield (6.03%) (40.23%) (31.76%)
Free cash flow yield (5.15%) (29.69%) (21.84%)

Profitability

Metric GYRE RGNX Biotechnology median
Gross margin 91.71% 87.54% 68.51%
Operating margin 0.00% (95.68%) 0.00%
Net margin (21.46%) (113.85%) 0.00%
Free cash flow margin (19.94%) (100.58%) 0.00%
Return on equity (18.54%) (113.24%) (50.82%)
Return on assets (14.49%) (35.36%) (46.04%)
Return on invested capital (8.51%) 0.00% 0.00%

Growth

Metric GYRE RGNX Biotechnology median
Revenue growth (TTM) 13.51% (4.59%) 6.96%
EPS growth (last fiscal year) (60.00%) 18.08% 29.88%
Revenue growth, 5-year CAGR 40.96% 1.97% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GYRE RGNX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.32 4.74 4.84
Net debt to EBITDA (3.74) 1.58 1.01

Dividend

Metric GYRE RGNX Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric GYRE RGNX Biotechnology median
Market cap 493.06m 533.60m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack